Elekta AB is a manufacturer of radiation therapy equipment—the machines that aim beams of energy at tumours with sub-millimetre precision. Headquartered in Stockholm and listed on the OMX Nordic Exchange Stockholm, the company operates in a concentrated global duopoly alongside Siemens Healthineers’ Varian unit. Elekta generates revenue through a classic model: it sells linear accelerators, Gamma Knife systems, and brachytherapy units to hospitals, then earns recurring income from service contracts, software licences, and upgrades for an installed base of over 7,000 systems across more than 120 countries.
At SEK 55.05, the stock trades at a market capitalisation of roughly SEK 21 billion. Forward valuation multiples sit at lower percentiles of their own ten-year history, such as EV/EBITDA NTM at 7.7x against 12.0x. Against European Healthcare peers, the discount narrows but remains firmly in the bottom quartile. The dividend yield has climbed to 4.36%, its 93rd historical percentile. Elekta presents the classic profile of a turnaround candidate at maximum uncertainty.
Our model projects that the 90% confidence interval spans from SEK 31.50 (P5) to SEK 101.35 (P95), meaning that in 90 out of every 100 simulated paths the final price lands within this range. The interquartile range — the middle 50% of outcomes, between SEK 44.41 (P25) and SEK 71.58 (P75) — offers a more pragmatic bracket for the likely investor experience.
The valuation is cheap by every metric that matters. The restructuring is well advanced, order momentum is accelerating, and the Evo platform has unlocked the critical US market. But the company still destroys value at the equity level, and leverage sits at historical extremes. The question is whether this operational momentum can close the gap between the market’s deeply pessimistic pricing and the company’s improving fundamentals.
The Fundamentals
Elekta’s financial profile suggests the company generates considerably more cash than its market valuation implies. The FCF Market Cap Yield stands at 32%—trailing free cash flow represents nearly a third of the company’s market capitalisation. This is an extraordinary figure, driven by working capital discipline (cash conversion at 91–92%, versus a 70% internal target) and a depressed share price that has mechanically magnified the yield. The FCF Yield of 12.58% sits at the 92nd percentile of its own history, reinforcing the same signal.
The Damodaran-adjusted ROE stands at −0.50%, confirming that Elekta is currently destroying value at the equity level once operating leases, R&D capitalisation, and off-balance-sheet items are accounted for. This is the core of the bear case: a company that cannot generate returns above its cost of equity should have a low valuation. A Net-Net Working Capital of −1.64€ per share indicates there is no liquidation safety margin. Any value, if present, must originate from an improvement in earning power.
The Cash Payout Ratio of 36.10% reveals a management team distributing roughly one third of cash earnings as dividends—a prudent level given the leverage situation. The current SEK 1.20 per share dividend is covered nearly three times by free cash flow (FCF/Dividend Coverage of 2.8x), making the 4.36% yield sustainable even in periods of low profitability. The Shareholder Yield of 2.97% adds net buyback activity to the picture, though a slightly negative debt payback yield (−1.53%) indicates modest net borrowing over the last twelve months. The company is balancing deleveraging with shareholder returns—not aggressively, but consistently.
The Total Debt/EBITDA ratio is 4.1x, ranking at the 100th percentile over the past decade. However, the Net Debt/(EBITDA − CAPEX) ratio of 12.44% provides the most informative perspective: after removing capital expenditures, the company maintains enough cash flow to fulfil its obligations. This situation is mainly due to a denominator issue—EBITDA's historical lows skew the ratios—rather than indicating systemic overleveraging. The trend towards deleveraging is evident, with net debt decreasing by SEK 700 million in H1 compared to the previous year.
Margins remain the weakest link. The EBITDA margin of 8.86% sits at its absolute ten-year low. Gross margin has drifted from the mid-40s pre-COVID to 38.51%, pressured by supply chain costs, single-source component dependencies, and tariff headwinds of roughly 100 basis points per quarter. However, the trajectory is improving: the adjusted EBIT margin climbed from 6.5% in Q1 to 11.9% in Q3 FY26, and management targets above 14% in the medium term.
Between the Lines
The company holds undisputed global leadership in Gamma Knife radiosurgery and a strong position in brachytherapy, reinforced by the 2023 acquisition of iCad’s Xoft division. In the Chinese linear accelerator market, Elekta commands a high market share—a legacy of decades of local engagement that gives it a meaningful presence in a region where Varian is relatively weaker. The MR-Linac (Unity platform), which combines magnetic resonance imaging with real-time radiation delivery, is a genuine technological differentiator with few direct competitors, though adoption remains niche and capital-intensive for buyers.
Elekta’s competitive position weakens in the US market and the broader external beam therapy segment, which together represent the largest revenue pool globally. Varian, now backed by Siemens Healthineers’ financial muscle and cross-selling network, holds an estimated 55–60% global share of the linac market, compared with Elekta’s 32–34%. The TrueBeam platform remains the de facto clinical standard in the United States. Siemens’ single-vendor proposition—bundling imaging, therapy, and software under one contract—gives Varian a structural advantage in large institutional procurement decisions. Elekta’s pure-play focus on radiation therapy means it cannot replicate this integrated offering, leaving it more exposed to competitive displacement when hospitals consolidate suppliers.
Meanwhile, United Imaging is emerging as a credible low-cost competitor in China, potentially eroding one of Elekta’s most defensible regional positions. The Evo FDA clearance is a critical attempt to shift this dynamic in the US, but converting regulatory approval into sustained market share gains against an entrenched incumbent will require flawless commercial execution.
Could the Elekta Reset restructuring bridge the gap between current bottom-line profitability and the 14% EBIT margin ambition? If it can, the re-rating potential is substantial: a return to the ten-year median EV/EBITDA of 12.0x from the current 7.7x implies roughly 55% upside before any margin recovery is factored in. The sequence of improving book-to-bill ratios, three consecutive quarters of margin expansion, and the near-completion of a large restructuring programme all point towards an inflection.
Risk Modelling
The Monte Carlo simulation ran over a 252-trading-day horizon (~12 months) using a hybrid GARCH + Historical Flexible Probabilities with t-Student distributions. Annualised volatility stands at 37.69%, with GARCH persistence of 0.9924, indicating strong volatility clustering. The equilibrium drift of 4.19% is derived from a risk-free rate of 2.79% plus an equity risk premium of 4.86%.
The simulation projects a median return of +2.43% and a mean return of +9.22%. The gap between mean and median reflects the distribution’s positive skewness: when gains occur, they tend to be proportionally larger than losses, pulling the average upward and away from the typical experience. Excess kurtosis of 2.98 confirms fat tails on both sides.
We can use the probability distribution as a map of where Elekta's share price is most likely to be over the next twelve months:
There is a 75% chance the stock will trade above SEK 44.41 — roughly 19% below today's price — meaning three out of four simulated futures see the share price hold above that floor, even after accounting for the stock's considerable volatility.
There is a 50% probability the price will exceed SEK 56.39, slightly above its current level, and a one-in-four chance it will clear SEK 71.58, representing an upside of more than 30%.
At the extremes, the simulation suggests only a 5% probability of the stock falling below SEK 31.50, while symmetrically, there is a 5% chance it will surpass SEK 101.35, almost doubling from here.
The overall shape of these probabilities tells a story of cautious asymmetry: the downside is real and should not be dismissed, but the distribution leans gently in the investor's favour, with probability-weighted gains outpacing losses across most thresholds.
Tail risk is significant. The VaR 95% at −42.78% represents the maximum expected loss 19 times out of 20, while the CvaR 95% at −50.28% captures the average loss in the worst 5% of outcomes. The median maximum drawdown is −30.7%, meaning the typical simulated path experiences a roughly one-third peak-to-trough decline at some point during the year. These numbers are consistent with a volatile mid-cap stock during a restructuring.
The Omega Ratio at the risk-free rate (2.79%) is the most informative single risk-adjusted metric in this analysis. Unlike the Sharpe Ratio (0.159) and Sortino Ratio (0.436), which summarise the entire return distribution in its first two moments—mean and variance—the Omega Ratio integrates over the full distributional shape, capturing asymmetry, fat tails, and every percentile of the distribution in a single number.
At the risk-free threshold, an Omega of 1.539 means that for every unit of probability-weighted shortfall below the risk-free rate, there are 1.54 units of probability-weighted excess return above it. When Elekta’s price moves higher, the magnitude of gains tends to exceed that of losses, creating a probability-weighted asymmetry that tilts the balance in the investor’s favour.
Model limitations: The model captures volatility dynamics but does not incorporate discrete forward-looking catalysts such as the Capital Markets Day, Evo commercial conversion, or cost-savings realisation. Dividends are not modelled in the price paths, so the simulation likely understates total investor returns. The fundamental analysis captures these qualitatively, providing a constructive complement to the conservative quantitative baseline.
The Upside
The upcoming Capital Markets Day in June 2026 is the most significant near-term catalyst. If management provides credible mid-term targets—such as an EBIT margin above 14%, around 6% organic revenue growth, and a transparent capital allocation framework—the event could trigger a re-rating by giving the market a concrete plan to estimate recovery. Currently, the valuation reflects minimal expectations for improvement, so even slight positive guidance could boost the stock.
With 83% of the cost-savings programme already executed, the remaining tranche should flow through to Q1 results in August 2026, offering the first clean quarter reflecting the full restructuring benefit. If the adjusted EBIT margin consistently exceeds 14%, the stock’s ten-year median EV/EBITDA of 12.0x—compared with the current 7.7x—becomes a reasonable basis for reevaluation.
The US market is the biggest untapped opportunity. The Evo CT-Linac platform gained FDA 510(k) clearance in January 2026, opening the US market where Elekta has historically lagged. This approval has already led to double-digit growth in orders in Q3, but US revenue remains about 20% of the total—far below the market potential, given Elekta's historical underperformance compared with Varian.
In China, a return to the normalised level of approximately 340 units annually, backed by a book-to-bill ratio of 1.14, would provide additional volume growth. The overall radiation therapy market is expanding at an estimated 6% CAGR, fuelled by underpenetration in emerging markets, creating a steady environment that benefits companies capable of maintaining their competitive edge.
The Downside
The most consequential risk is the failure to execute the Elekta Reset programme. Restructurings of this magnitude—cutting 10% of the workforce, collapsing management layers, and decentralising P&L responsibility—frequently create revenue dis-synergies before cost savings fully materialise. If the programme delivers less than SEK 500 million, or if the organisational disruption impairs commercial effectiveness, margins may remain below 12% and the re-rating thesis evaporates. The key signal to watch is book-to-bill: a decline below 1.0x would indicate that cost-cutting is damaging the order pipeline.
Siemens Healthineers' competitive pressure remains a significant challenge. Varian’s integration within the Siemens ecosystem has enhanced its bundled offerings. The impending launch of a next-generation linear accelerator could intensify competition, especially as Elekta seeks to expand with the Evo platform. In the US, where Varian’s TrueBeam is the standard, translating FDA approval into increased market share is difficult. If US order growth drops below 5%, it could signal an early warning for the business.
For Elekta, which manufactures in Sweden and the United Kingdom and exports to the United States, tariffs remain unpredictable. The current Section 232 investigation is imposing an approximate 100-basis-point drag on gross margins each quarter, with a potential escalation that could double that impact. Additionally, currency headwinds, mainly from a strong Swedish krona, are contributing about 130 basis points of pressure. Overall, these external factors consistently challenge reported margins.
Finally, in China, the emergence of government-supported local competitors such as United Imaging threatens what has been one of Elekta’s most profitable and defensible regional positions. A decline in gross margin below 37% would signal that these pressures are overwhelming the cost-savings programme.
DISCLAIMER
The information provided in this newsletter is for educational and informational purposes only and does not constitute investment advice, financial advice, trading advice, or any other type of advice. The content should not be interpreted as an offer, solicitation, or recommendation to buy, sell, or hold any financial instrument.
The author is not a licensed financial advisor, broker, or dealer and is not authorised or regulated by any financial supervisory authority. All investment decisions involve risk, including the potential loss of principal. Past performance is not indicative of future results. Readers should conduct their own research before making any investment decisions.